Compass Therapeutics, Inc.(CMPX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMPX Compass Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

5.16

-0.23

-4.27%

盘后5.19

+0.03+0.58%

19:51 EST

High5.43	Low5.15	Vol1.18M
Open5.38	D1 Closing5.39	Amplitude5.19%
Mkt Cap917.77M	Tradable Cap634.94M	Total Shares177.86M
T/O6.25M	T/O Rate0.96%	Tradable Shares123.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMPX","market":"US","secType":"STK","nameCN":"Compass Therapeutics, Inc.","latestPrice":5.16,"timestamp":1765573200000,"preClose":5.39,"halted":0,"volume":1181449,"hourTrading":{"tag":"盘后","latestPrice":5.19,"preClose":5.16,"latestTime":"19:51 EST","volume":23683,"amount":122284.9038,"timestamp":1765587080262},"delay":0,"floatShares":123050081,"shares":177862102,"eps":-0.451203,"marketStatus":"Market Closed","change":-0.23,"latestTime":"12-12 16:00:00 EST","open":5.38,"high":5.43,"low":5.15,"amount":6245341.8914,"amplitude":0.051948,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.451203,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1605243600000,"exchange":"NASDAQ","adjPreClose":5.39,"preHourTrading":{"tag":"盘前","latestPrice":5.38,"preClose":5.39,"latestTime":"09:26 EST","volume":620,"amount":3296.24519,"timestamp":1765549615684},"postHourTrading":{"tag":"盘后","latestPrice":5.19,"preClose":5.16,"latestTime":"19:51 EST","volume":23683,"amount":122284.9038,"timestamp":1765587080262},"volumeRatio":0.8090659242136767,"impliedVol":0.7394,"impliedVolPercentile":0.4528},"requestUrl":"/m/hq/s/CMPX","defaultTab":"news","newsList":[{"id":"2588046598","title":"Compass Therapeutics Initiated at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046598?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:44","pubTimestamp":1764765840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 07:44 ET (12:44 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2588045340","title":"Cantor Fitzgerald Initiates Compass Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045340?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:14","pubTimestamp":1764764083,"startTime":"0","endTime":"0","summary":"Compass Therapeutics (CMPX) has an average rating of buy and mean price target of $12.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMPX"],"gpt_icon":0},{"id":"2586763259","title":"Compass Therapeutics Inc. : Leerink Partners Raises Target Price to $11 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2586763259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586763259?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:52","pubTimestamp":1764157936,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2582875152","title":"Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875152?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:18","pubTimestamp":1762777127,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Compass Therapeutics, with a price target of $12.00. Amin cove...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/compass-therapeutics-cmpx-receives-a-buy-from-piper-sandler-blurbs-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/compass-therapeutics-cmpx-receives-a-buy-from-piper-sandler-blurbs-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2581884790","title":"Compass Therapeutics Inc.  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581884790","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581884790?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:33","pubTimestamp":1762529598,"startTime":"0","endTime":"0","summary":"Compass Therapeutics Inc.  expected to post a loss of11cents a share - Earnings Preview Compass Therapeutics Inc. CMPX.OQ CMPX.O is expected to  show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ25W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2581870345","title":"Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2581870345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581870345?lang=en_us&edition=fundamental","pubTime":"2025-11-06 02:55","pubTimestamp":1762368931,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Charles Zhu has maintained their bullish stance on CMPX stock, giving a Buy rating on October 27. Charles Zhu has given his...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-compass-therapeutics-buy-rating-justified-by-promising-developments-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-compass-therapeutics-buy-rating-justified-by-promising-developments-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPX"],"gpt_icon":0},{"id":"2581773581","title":"Compass Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581773581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581773581?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:56","pubTimestamp":1762350960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 08:56 ET (13:56 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX"],"gpt_icon":0},{"id":"2581722598","title":"Compass Therapeutics Q3 EPS $(0.08) Beats $(0.14) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722598","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722598?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:34","pubTimestamp":1762346096,"startTime":"0","endTime":"0","summary":"Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.14) by 43.66 percent. This is unchanged from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649895/compass-therapeutics-q3-eps-0-08-beats-0-14-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX"],"gpt_icon":0},{"id":"2581722841","title":"Compass Therapeutics posts $14.3 million net loss for third quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722841","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722841?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:31","pubTimestamp":1762345904,"startTime":"0","endTime":"0","summary":"Compass Therapeutics Inc. reported a net loss of $14.3 million for the three months ended September 30, 2025, compared to a net loss of $10.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $50.8 million, up from $34.3 million in the prior year period. Research and development expenses increased by 44% to $42.3 million for the nine months ended September 30, 2025, primarily due to higher manufacturing and IND-enabling costs related to tovecimig and CTX-10726. Other income decreased by 29% to $3.9 million for the nine months ended September 30, 2025, due to lower interest income from reduced average cash and marketable securities balances. The company has not generated revenue from the sale of products and continues to fund operations primarily through equity securities, with $568 million raised in gross proceeds to date.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLZMQL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2581722922","title":"Compass Therapeutics Inc. - Expects Phase 2/3 Companion-002 Study of Tovecimig Os and Pfs Data in Late Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722922?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLXFF0851:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2581688722","title":"Compass Therapeutics Q3 EPS USD -0.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2581688722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581688722?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLXFF0851:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2581272477","title":"Compass Therapeutics Q3 Net Income USD -14.259 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581272477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581272477?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLXFF0851:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPX"],"gpt_icon":0},{"id":"2581229407","title":"Compass Therapeutics Inc. - Plans Ctx-10726 Ind Filing for Q4 2025 With Initial Phase 1 Clinical Data Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581229407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581229407?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLXFF0851:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2581722202","title":"Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722202","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722202?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345800,"startTime":"0","endTime":"0","summary":"Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181347/0/en/Compass-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","BK4211","BTC","BK4139","BK4080","BK4231","OS","BK4097","SITC","BK4195","PFS"],"gpt_icon":0},{"id":"2577807737","title":"Compass Therapeutics management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2577807737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577807737?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:50","pubTimestamp":1761079822,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on October 23-27 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-movi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-therapeutics-management-to-meet-with-piper-sandler-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-therapeutics-management-to-meet-with-piper-sandler-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CMPX"],"gpt_icon":0},{"id":"2575107244","title":"Buy Rating for Compass Therapeutics Driven by Promising Clinical Trial Data and Strategic Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2575107244","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575107244?lang=en_us&edition=fundamental","pubTime":"2025-10-13 05:15","pubTimestamp":1760303712,"startTime":"0","endTime":"0","summary":"Compass Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Charles Zhu from LifeSci Capital mai...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-compass-therapeutics-driven-by-promising-clinical-trial-data-and-strategic-enrollment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-compass-therapeutics-driven-by-promising-clinical-trial-data-and-strategic-enrollment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPX"],"gpt_icon":0},{"id":"2573674537","title":"Compass Therapeutics Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2573674537","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573674537?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:53","pubTimestamp":1759751580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 06, 2025 07:53 ET (11:53 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX"],"gpt_icon":0},{"id":"2572557948","title":"Compass Therapeutics management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2572557948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572557948?lang=en_us&edition=fundamental","pubTime":"2025-10-02 04:20","pubTimestamp":1759350027,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on October 8 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-therapeutics-management-to-meet-with-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-therapeutics-management-to-meet-with-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2559984506","title":"Compass Therapeutics Inc. Files Prospectus for Proposed Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2559984506","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559984506?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:07","pubTimestamp":1755119258,"startTime":"0","endTime":"0","summary":"Compass Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in antibody-based therapeutics for oncology, has announced the filing of a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission. The registration, which was declared effective on September 6, 2024, pertains to an underwritten public offering of common stock and pre-funded warrants. Jefferies, Piper Sandler, and Guggenheim Securities are managing the offering. Compass plans to utilize the proceeds for commercial readiness, research, clinical development, and general corporate purposes. The offering will be made via a prospectus and prospectus supplement available through the SEC and the involved financial institutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL4Qc5NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4139","PIPR","CMPX"],"gpt_icon":0},{"id":"2559675508","title":"BRIEF-Compass Therapeutics Announces Pricing Of Upsized $120 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2559675508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559675508?lang=en_us&edition=fundamental","pubTime":"2025-08-13 10:28","pubTimestamp":1755052113,"startTime":"0","endTime":"0","summary":"BRIEF-Compass Therapeutics Announces Pricing Of Upsized $120 Million Public OfferingAug 12 (Reuters) - Compass Therapeutics Inc. CMPX.O:COMPASS THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $120 MILLION P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUA7XPRLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.compasstherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0669},{"period":"1month","weight":0.0531},{"period":"3month","weight":0.4454},{"period":"6month","weight":1.1411},{"period":"1year","weight":2.4172},{"period":"ytd","weight":2.5586}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.100326},{"month":2,"riseRate":0.5,"avgChangeRate":0.094338},{"month":3,"riseRate":0.25,"avgChangeRate":-0.173699},{"month":4,"riseRate":0.25,"avgChangeRate":-0.07325},{"month":5,"riseRate":0.4,"avgChangeRate":0.146493},{"month":6,"riseRate":0.6,"avgChangeRate":0.008734},{"month":7,"riseRate":0.6,"avgChangeRate":0.017507},{"month":8,"riseRate":0.6,"avgChangeRate":0.058578},{"month":9,"riseRate":0.4,"avgChangeRate":-0.036741},{"month":10,"riseRate":0.4,"avgChangeRate":0.029035},{"month":11,"riseRate":0.6,"avgChangeRate":0.162335},{"month":12,"riseRate":0.2,"avgChangeRate":-0.010295}],"exchange":"NASDAQ","name":"Compass Therapeutics, Inc.","nameEN":"Compass Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Compass Therapeutics, Inc.(CMPX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Compass Therapeutics, Inc.(CMPX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Compass Therapeutics, Inc.,CMPX,Compass Therapeutics, Inc.股票,Compass Therapeutics, Inc.股票老虎,Compass Therapeutics, Inc.股票老虎国际,Compass Therapeutics, Inc.行情,Compass Therapeutics, Inc.股票行情,Compass Therapeutics, Inc.股价,Compass Therapeutics, Inc.股市,Compass Therapeutics, Inc.股票价格,Compass Therapeutics, Inc.股票交易,Compass Therapeutics, Inc.股票购买,Compass Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Compass Therapeutics, Inc.(CMPX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Compass Therapeutics, Inc.(CMPX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}